Retraction
Emodin Attenuates Lipopolysaccharide-Induced Injury via Down-Regulation of miR-223 in H9c2 Cells
Paper Information
Record ID:
35091
Author(s):
Publication Date:
February 08, 2019
Retraction Date:
January 29, 2022
(3.8 years years ago)
Subjects:
Institutions:
Country:
🇨🇳 ChinaArticle Type:
Publisher:
International Heart Journal Association
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (15)
15
Total Citations7
Post-Retraction(46.7%)
8
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
0
Within 30 days
1
Within 1 year
2
After 2+ years
1224
Days since retraction (latest)
Emodin-Induced ERα Degradation via SYVN1 Alleviates Vascular Calcification by Preventing HIF-1α Deacetylation in Chronic Kidney Disease
Yongyan Chen, Han Xu, Yuxuan Hao et al. (9 authors)
Phytomedicine
Published: Jun 2025
1224 days after retraction
Quinones in the treatment of cardiovascular diseases
Md. Khokon Miah Akanda, Sanzia Mehjabin, Ashik Mosaddik
Elsevier eBooks
Published: Nov 2024
2 citations
2 citations
1007 days after retraction
Advances in the pharmacological effects and molecular mechanisms of emodin in the treatment of metabolic diseases
Linyuan Yu, Yongliang Zhao, Yongli Zhao
Frontiers in Pharmacology
Open Access
Published: Oct 2023
15 citations
15 citations
640 days after retraction
Role of MicroRNAs in Dietary Interventions for Obesity and Obesity-Related Diseases
J.H. Zhang, Chaoqin Ren, Yanan Cao et al. (7 authors)
Journal of Agricultural and Food Chemistry
Published: Oct 2023
6 citations
6 citations
611 days after retraction
Herbal Medicine for Cardiovascular Disease in View of Avicenna
Zahra Taghipour, Mamak Hashemi Habib Abadi
CABI eBooks
Published: Sep 2023
609 days after retraction
Revealing Landscape of Competing Endogenous RNA Networks in Sepsis-Induced Cardiovascular Diseases
Wei Xiong, Shiyan Feng, Yanhua Zhao et al. (5 authors)
Reviews in Cardiovascular Medicine
Open Access
Published: Jul 2023
1 citation
1 citation
541 days after retraction
Emodin in cardiovascular disease: The role and therapeutic potential
Yuanyuan Guo, Rongzhen Zhang, Wenlan Li
Frontiers in Pharmacology
Open Access
Published: Dec 2022
10 citations
10 citations
328 days after retraction
Effects of Emodin on Alveolar Bone Resorption via the IL-23/Th17 Inflammatory Axis in Rats with Periodontitis
Chunfeng Wang, Yuxian Li, Yepo Hou et al. (5 authors)
Journal of Hard Tissue Biology
Open Access
Published: Jan 2022
28 days before retraction
Emodin prevents renal ischemia-reperfusion injury via suppression of CAMKII/DRP1-mediated mitochondrial fission
Yanqing Wang, Qian Liu, Jiaying Cai et al. (14 authors)
European Journal of Pharmacology
Published: Nov 2021
39 citations
39 citations
74 days before retraction
Advances in the study of emodin: an update on pharmacological properties and mechanistic basis
Qi Zheng, Shuo Li, Xiaojiaoyang Li et al. (4 authors)
Chinese Medicine
Open Access
Published: Oct 2021
67 citations
67 citations
111 days before retraction
Emodin: A metabolite that exhibits anti-neoplastic activities by modulating multiple oncogenic targets
Hardeep Singh Tuli, Vaishali Aggarwal, Muobarak J. Tuorkey et al. (10 authors)
Toxicology in Vitro
Published: Mar 2021
23 citations
23 citations
317 days before retraction
Molecular Mechanisms of Action of Emodin: As an Anti-Cardiovascular Disease Drug
Qianqian Li, Jian Gao, Xiaohan Pang et al. (5 authors)
Frontiers in Pharmacology
Open Access
Published: Aug 2020
65 citations
65 citations
520 days before retraction
Emodin improves the cardiac function in the rats with chronic heart failure through regulation of the miR-26b-5p/PTEN pathway
Zuncai Gu, Shuhua Zhang, Siyuan Zhao et al. (5 authors)
Archives of Medical Science
Open Access
Published: Jun 2020
1 citation
1 citation
593 days before retraction
Kanglexin, a novel anthraquinone compound, protects against myocardial ischemic injury in mice by suppressing NLRP3 and pyroptosis
Yu Bian, Xin Li, Ping Pang et al. (12 authors)
Acta Pharmacologica Sinica
Open Access
Published: Oct 2019
78 citations
78 citations
829 days before retraction
Isosibiricin inhibits microglial activation by targeting the dopamine D1/D2 receptor-dependent NLRP3/caspase-1 inflammasome pathway
Yan-Hang Wang, Hai‐Ning Lv, Qinghua Cui et al. (6 authors)
Acta Pharmacologica Sinica
Open Access
Published: Sep 2019
27 citations
27 citations
872 days before retraction
Quick Stats
Total Citations:
15
Years Since Retraction:
3.8 years
Open Access:
Yes
Last Checked:
Jul 24, 2025